Bristol Myers Squibb (BMY) Long-Term Deferred Tax (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Long-Term Deferred Tax for 18 consecutive years, with $5.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 15.39% year-over-year to $5.4 billion in Q2 2026; TTM through Jun 2026 was $5.4 billion, a 15.39% increase from a year earlier, with the FY2025 full-year figure at $5.4 billion, up 26.96% from the prior year.
• Long-Term Deferred Tax was $5.4 billion for Q2 2026 at Bristol Myers Squibb, up from $5.2 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $5.4 billion in Q4 2025 and troughed at $1.3 billion in Q1 2023.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2023 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax decreased 7.12% in 2023 and jumped 138.38% in 2024, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $1.3 billion in 2022, then jumped by 105.95% to $2.8 billion in 2023, then jumped by 53.03% to $4.2 billion in 2024, then gained by 26.96% to $5.4 billion in 2025, then fell by 0.3% to $5.4 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $5.4 billion (Q2 2026), $5.2 billion (Q1 2026), and $5.4 billion (Q4 2025), per Business Quant data.